Skip to Content
Merck
  • Discovery of 6-chloro-2-trifluoromethyl-7-aryl-7H-imidazo[1,2-a]imidazol-3-ylmethylamines, a novel class of corticotropin-releasing factor receptor type 1 (CRF1R) antagonists.

Discovery of 6-chloro-2-trifluoromethyl-7-aryl-7H-imidazo[1,2-a]imidazol-3-ylmethylamines, a novel class of corticotropin-releasing factor receptor type 1 (CRF1R) antagonists.

Bioorganic & medicinal chemistry letters (2010-05-18)
Dmitry Zuev, Vivekananda M Vrudhula, Jodi A Michne, Bireshwar Dasgupta, Sokhom S Pin, Xiaohua Stella Huang, Dedong Wu, Qi Gao, Jie Zhang, Matthew T Taber, John E Macor, Gene M Dubowchik
ABSTRACT

A novel series of [6-chloro-2-trifluoromethyl-7-aryl-7H-imidazo[1,2-a]imidazol-3-ylmethyl]-dialkylamines was discovered as potent CRF(1)R antagonists. The optimization of binding affinity in the series by the parallel reaction approach is discussed herein.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
2-Methylpiperidine, 98%